Metsera (NASDAQ:MTSR) Trading Up 11.6% – What’s Next?

Metsera, Inc. (NASDAQ:MTSR)’s stock price shot up 11.6% on Monday . The company traded as high as $28.40 and last traded at $27.66. 133,137 shares traded hands during trading, a decline of 77% from the average session volume of 589,322 shares. The stock had previously closed at $24.78.

Wall Street Analyst Weigh In

Several analysts recently issued reports on MTSR shares. Guggenheim assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price target for the company. Cantor Fitzgerald initiated coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating on the stock. Bank of America assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 target price for the company. Finally, Evercore ISI assumed coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued an “outperform” rating on the stock.

Metsera Stock Up 13.4 %

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.